Therefore, HER2-specific peptide ligands have gained attention; for example, Karasseva et al. developed KCCYSL peptide using the phagedisplaytechnique and demonstrated its activities against human breast and prostate cancer cells with HER2 overexpression [116]. Here, ERBB2 is linked to prostate carcinoma.